With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Industries included in the sector are diversified and specialty chemical manufacturers.

Fortune Sector Leaders: Chemicals

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

This year’s Fortune 500 marks the 68th running of the list.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-144-DuPont

To say that DuPont has been through a lot of changes in recent years would be an understatement. In 2017, DuPont completed a $130 billion merger of equals with Dow to form DowDuPont, one of the world's biggest chemical companies. Then, in 2019, the chemical giant split apart again, this time into three separate companies—Dow, Corteva, and DuPont. Since then, DuPont has been reshuffling its businesses, most recently completing the separation of its nutrition and biosciences operation and signing agreements to divest its clean technologies and advanced solar cell materials businesses. The company expects to generate about $8 billion from the three transactions.

Collectively, the ranked companies produced a three-year average shareholder return of 33%, vs. 19% for the S&P 500.

FGC 2021-DuPont

100 Fastest-Growing Companies

This year's Fortune 500 marks the 66th running of the list.

F500-2020-152-Dupont

One of the three companies to emerge from the breakup of DowDuPont in 2019—just two years after a historic merger—the new DuPont is focused on specialty industrial materials such as Tyvek, used in personal protective gear. In April, the company said it would double its production of garments made with Tyvek to meet high demand resulting from the coronavirus.

This year's Fortune Global 500 generated $27.7 trillion in revenues and $1.5 trillion in profits.

Fortune Global 500

This year's Fortune 500 marks the 65th running of the list.

These 52 companies from across the globe are doing well by doing good.

Change the World

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

World's Most Admired Companies

This year's Fortune 500 marks the 64th running of the list.

This year's Fortune 500 marks the 63rd running of the list.

This year's Fortune Global 500 generated $27.6 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 62nd running of the list.

The world's 500 largest companies generated $31.2 trillion in revenues and $1.7 trillion in profits in 2014. Together, this year's Fortune Global 500 employ 65 million people worldwide and are represented by 36 countries.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Global business is back. After limping through a worldwide financial crisis and economic slowdown, the 500 largest companies ranked by revenues shattered all sorts of performance records in 2013: They racked up combined revenues of $31.1 trillion, up 2.5% from 2012, and profits soared 27% to nearly $2 trillion. China’s 95 companies (up from 89 last year) posted $5.8 trillion in revenues. The U.S. has four fewer companies on the list than last year but remains (for now) the country leader, with 128 corporations on the list—including No. 1 Wal-Mart Stores—reporting $8.6 trillion in revenues. 

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Company Info

Industry

Location

Industry Rank

Website

Overall Score

Key Attributes Of Reputation

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Fastest-growing Companies

Revenue 3 Yr Growth Rank

Revenue 3 Yr Annual Growth Rate

EPS 3 Yr Growth Rank

EPS 3 Yr Annual Growth Rate

Total Return 3 Yr Rank

Total Return 3 Yr Annual Rate

Beat S&P 500 3 Yr Return

Years on List

Sector

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

DuPont de Nemours manufactures specialty chemicals. The electronics and industrial segment supplies materials for the fabrication of semiconductors and integrated circuits. The water and protection segment provides engineered products and integrated systems for worker safety, water purification and separation, transportation, energy, medical packaging, and building materials. The corporate and other segment offers auto adhesives and fluids as well as Multibase and Tedlar products.

Q3 2026

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

DuPont (DD): Company Profile, Stock Price, News, Rankings

legacy

DuPont

dupont

Thank you for standing by, and welcome to the DuPont third quarter 2026 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during that time, simply press star, then the number one on your telephone keypad. I would now like to turn the call over to Ann Giancristoforo, Vice President of Investor Relations. Please go ahead.

Good morning, and thank you for joining us for DuPont's third quarter 2026 financial results conference call. Joining me today are Lori Koch, Chief Executive Officer, and Antonella Franzen, Chief Financial Officer. We have prepared slides to supplement our remarks, which are posted on DuPont's website under the Investor Relations tab and through the webcast link. Please read the forward-looking statement disclaimer contained in the slides. During this call, we will make forward-looking statements regarding our expectations or predictions about the future. Because these statements are based on current assumptions and factors that involve risks and uncertainties, our actual performance and results may differ materially from our forward-looking statements. Our Form 10-K, as updated by our current and periodic reports, includes detailed discussion of principal risks and uncertainties which may cause such differences.

Unless otherwise specified, all historical financial measures presented today are on a continuing operations basis and exclude significant items. We will also refer to other non-GAAP measures. A reconciliation to the most directly comparable GAAP financial measure is included in our press release and presentation materials and has been posted to DuPont's Investor Relations website. Consistent with our prior earnings calls, we will provide comments on our results versus the prior year pro forma, which adjusts for our post-separation corporate costs, interest expense, and income tax rate. This is consistent with the methodology and financial metrics that we provided at our 2025 Investor Day. I'll now turn the call over to Lori, who will begin on slide three.

Good morning, and thanks, everyone, for joining our call. Earlier today, we reported our third quarter financial results, which again exceeded our previously communicated guidance, demonstrating the strength of our portfolio and the consistent execution of our team. Broad-based sales growth combined with a continued focus on productivity enabled organic growth of 5%, 90 basis points of margin expansion, 31% adjusted EPS growth, and robust free cash flow conversion in the quarter. As a result of our performance, we are again raising our full year 2026 financial guidance for organic sales growth, operating EBITDA, and adjusted EPS, all at or above the high end of our previously communicated range. Antonella will provide further details shortly. We also continue to execute our capital allocation priorities. We completed the previously announced $250 million ASR and substantially completed an additional $100 million of open market purchases in the quarter.

We also announced our intention to repurchase another $250 million of shares in the fourth quarter. This underscores our confidence in DuPont's long-term growth potential and reinforces our focus on allocating capital where we see compelling return opportunities, including investing in our own shares. Overall, this was another solid quarter of strong execution. We delivered strong organic growth, expanded margins, generated robust free cash flow, and returned meaningful capital to shareholders, all while continuing to advance our strategic priorities. Moving to our strategic priorities on slide four. We continue to strengthen the operating framework that connects our culture, planning, and execution. Our focus remains on accountability, productivity, and performance excellence, with the objective of building a more consistent and sustainable growth engine. Innovation excellence continues to strengthen DuPont's ability to turn differentiated technologies and application expertise into opportunities for sustainable growth.

We are enhancing the quality of our innovation portfolio through more rigorous portfolio management, stronger visibility to accretive growth opportunities, and differential resource allocation. In the past quarter, we substantially increased our front-end innovation pipeline and increased the grow versus renew ratio of our innovation portfolio by about 5%, ensuring that our vitality index remains strong in the mid-30% range. The results are increasingly visible across our growth markets. In Water Technologies, we expanded our bioprocessing portfolio with a new purification technology aimed at the fast-growing peptide therapeutics market, including GLP-1 drugs. This product helps pharmaceutical manufacturers achieve the purity, yield, and scale needed to meet rising demand for these therapies. In addition, we launched Tyvek with Renewable Attribution in the quarter, which provides customers with a solution that maintains the superior performance they know while supporting progress on sustainable material sourcing and carbon footprint reduction.

Commercially, we continue to see strong order patterns, with the total company order book solidly up double digits year-over-year. In addition, we are strengthening the connection across innovation, marketing, and sales into a more systemic growth engine, enabling better win rates, faster activation of sales plays, stronger launch readiness, and more disciplined execution from opportunity creation through conversion. The focus on this connection is driving key customer wins. Our adhesive business recently secured a customer win with BETATECH, an advanced thermal material that maintains optimal battery temperatures and helps automakers enhance vehicle performance, reliability, and circularity. Our Vespel custom-engineered seals were recently selected for their exceptional durability, wear resistance, and thermal stability, enabling safe, reliable fuel transfer during launch operations and showcasing our ability to solve complex aerospace challenges.

In addition, we were recently awarded the largest containerized desalination project in EMEA, where our ultrafiltration modules provide greater efficiencies from a cost and space perspective, increasing the amount of clean drinking water that can be produced in each container. Operational excellence continues to deliver measurable results. We completed more than 20 Kaizen events during the quarter across our businesses and functions, with a continued focus on safety, quality, delivery, inventory, and cost. We are seeing the results of this work in our key performance indicators, delivering over 2% net productivity in the quarter, which was also a key component of our margin expansion. Additionally, our OTIF improved by more than 100 basis points, marking the third consecutive quarter of improvement. More broadly, the adoption of AI tools continues to accelerate as we work to connect our business system framework to AI-enabled toolsets.

We are seeing faster and better decision-making from our teams on the factory floor, where we are starting to realize material benefits in the areas of planning and quality. Our 2026 financial performance continues to demonstrate the strength and quality of our portfolio, positioning us above the high end of all of the medium-term targets we established at Investor Day. We have a strong foundation for consistent profitable growth, supported by attractive end market exposure, continued operating leverage, and robust cash generation. We will enter 2027 with confidence in our ability to execute and the significant opportunity we have to drive earnings growth and create long-term shareholder value. With that, I will now turn the call over to Antonella to cover the financials and outlook in more detail.

Thanks, Lori, and good morning, everyone. Strong operational execution and broad-based growth drove another quarter of results ahead of our financial guidance. Organic growth and disciplined productivity translated into strong operating leverage and meaningful margin expansion. Additionally, our businesses continue to convert earnings into cash at a high rate, giving us significant financial flexibility. Beginning with our third quarter financial highlights on slide five. Net sales of $1.9 billion were up 4% versus the year-ago period on 5% organic sales growth, partially offset by a 1% headwind from currency. Top-line growth was broad-based, led by continued strength in healthcare and aerospace, as well as year-over-year growth in Building Technologies on gains in North America and Asia. From a segment view, during the quarter, organic sales grew 4% in Healthcare & Water Technologies and 5% in Diversified Industrials.

Third quarter operating EBITDA of $469 million increased 8% versus the year-ago period on organic sales growth and productivity. This resulted in operating EBITDA margin of 25.1% in the quarter, an increase of 90 basis points year-over-year. Turning to cash flow, we delivered transaction-adjusted free cash flow of $341 million and related conversion of 121%, underpinned by earnings growth and net working capital productivity. Based on our year-to-date results, we now expect our full-year free cash flow conversion to be approximately 100%, nicely ahead of our 90% target. Turning to slide six. Adjusted EPS for the quarter of $2.09 was up 31% versus the year-ago period. Stronger operations, benefits from higher cash, capital allocation, and actions taken to lower the tax rate drove 24% of the increase. Turning to our segment results on slide seven.

Healthcare & Water Technologies' third quarter net sales of $865 million were up 4% versus the year-ago period on 4% organic growth. For the third quarter, healthcare sales were up mid-single digits percent on an organic basis versus the year-ago period. Organic growth was led by double-digit gains in personal protection and medical packaging. Water sales were up low single digits percent on an organic basis on strength in industrial water and double-digit gains in semiconductor and specialty markets, partially offset by continued disruptions in the Middle East. Excluding the Middle East, organic sales increased mid-single digits percent in the quarter. Operating EBITDA for the segment during the quarter of $263 million was up 7% versus the year-ago period on organic growth and productivity gains. Strong operating leverage resulted in operating EBITDA margin of 30.4%, an increase of 80 basis points year-over-year.

Turning to Diversified Industrials. Third quarter net sales of $1 billion increased 4% versus the year ago period on 5% organic sales growth, partially offset by a 1% headwind from currency. At the line of business level, organic sales for Building Technologies were up mid-single digits percent on growth in North America and Asia. Growth in North America was broad-based, led by share gains and building envelopes for residential markets. Industrial Technologies organic sales were up mid-single digits percent on double-digit gains in aerospace and EV battery applications. Operating EBITDA for Diversified Industrials of $242 million was up 11% versus the year ago period on organic growth and productivity. This translated to operating EBITDA margin in the quarter of 24.1%, an increase of 140 basis points versus the year ago period. Turning to slide eight.

We are again raising our full year 2026 financial guidance with all metrics at or above the high end of our previously communicated range. For the full year 2026, our net sales guidance now assumes organic growth to be approximately 4.5%, reflecting our performance to date and continued strength across most of our key end markets. We now expect sales to be about $7.19 billion, an increase of $15 million from the midpoint of our prior guidance and at the top end of our prior guidance range. While we have the orders in hand for our large water projects in the Middle East, given the continued disruptions, our guidance now assumes these projects will be pushed into 2027. Continued strength in our other end markets allowed us to raise our guidance to the high end of our previous range.

Operating EBITDA is now expected to be $1.785 billion, an increase of $25 million from the midpoint of our prior guidance, reflecting our stronger third quarter results, as well as increased productivity benefits as we exit the year. Our operating EBITDA growth represents about 40% incremental and translates into margin of 24.8%, an 80 basis point improvement year-over-year. We continue to expect to fully offset higher input costs through pricing actions already taken. Our adjusted EPS at the midpoint of $7.50 is a $0.25 increase versus our prior guidance and represents a 22% increase compared to the prior year pro forma. Underlying business performance, coupled with the benefits from capital deployment, are driving the year-over-year increase.

For the fourth quarter, our estimated net sales of $1.825 billion assumes organic growth of about 8% year-over-year, driven by continued strength in healthcare, aerospace, and industrial water end markets, as well as pricing actions taken to offset higher input costs. As a reminder, our fourth quarter 2025 net sales included a headwind of $30 million or 2% from the order timing shift into the third quarter 2025 due to separation-related activities. Currency is expected to be neutral in the quarter. Operating EBITDA is expected to be $455 million, resulting in operating EBITDA margin of 24.9%. Adjusted EPS is expected to be in the range of $1.90 to $1.95 per share, representing an increase of 17%-19% compared to the prior year pro forma.

For the Healthcare & Water Technologies segment, we expect fourth quarter organic sales growth in the high single digits percent range, led by strength in personal protection, medical devices, and industrial water markets. For the Diversified Industrials segment, we expect fourth quarter organic sales growth in the high single digits percent range on continued strength in aerospace and EV battery applications. Before I close, I want to recognize and thank our teams around the world. Our strong performance this year is a direct reflection of their dedication, exceptional execution, and commitment to our customers. We have built strong momentum through the first nine months, and we remain focused on carrying that momentum through the balance of the year. With leading positions in attractive markets, a strong execution mindset, and an exceptional team, I am confident in our ability to finish the year strong.

With that, we are pleased to take your questions. Let me turn it back to the operator to open the Q&A.

As a reminder, if you would like to ask a question, press star, then the number 1 on your telephone keypad. To withdraw your question, simply press star one again. We kindly ask that you limit your questions to one and one follow-up for today's call. We will pause for just a moment to compile the Q&A roster. Our first question comes from the line of Jeff Sprague with Vertical Research Partners. Your line is open.

Hey, thank you. Good morning, everyone. Nice to see the volume and the internal initiatives all kind of coming together.

Okay, sorry about that. I wanted to see if we could unpack a little bit, just kind of the impact of the internal initiatives on what's going on with margins relative to the volume lift you must be getting. I'm sure you view yourself as relatively early in these internal initiatives, but maybe you could just give us a little perspective on the runway you have there.

Yeah, thanks, Jeff. We are seeing a lot of momentum on the productivity side. That was a big piece of the improvement that we saw in overall EBITDA margins in the quarter of about 90 basis points on a pro forma basis. Off to a really great start. We've mentioned that we're targeting a net 3% productivity in our COGS, meaning that we would drive a net 3% reduction there outside, obviously, volume increases. We're well on our way. In the quarter, we were a little over 2% net productivity, which drove about 100 basis points of the EBITDA margin lift that we saw in the quarter, which was slightly offset by some growth investments that we continue to make within the organization. Really nice improvement.

It's really coming from many different levers, not only improvements in cost of poor quality and volume variance with being able to get more production off of a fixed asset base, but also on the procurement side, especially in a tough market where obviously there's a lot of oil and gas headwinds. We are driving procurement savings as well. From a top line perspective, really nice improvement in OTIF and defect rate. We've made steady progress in OTIF. We target 95% as our ultimate target on a delivery to request date, not a delivery to promise, so even a higher bar for us, and we're in the low 80s now. Lots of room for improvement, but we've also made a fair amount of improvement, we're really happy with the progress.

Great. Then maybe just a more near-term question. Just the water-related projects in the Middle East that were sort of a question mark. So how much revenue was that you pushed out of your 2026 plan into next year? $25 million or so?

We actually pushed out about $15 million, Jeff.

Our next question comes from the line of Scott Davis with Melius Research. Your line is open.

Good morning, Lori and Antonella and Ann .

Congrats on a good couple, several quarters in a row here, improvement. Look, I wanted to move over a little bit on the innovation side. Jeff Sprague took my question on quality and delivery, which I think is really important for you guys. On the innovation side, this seems like something that is getting some sort of traction. Is it possible to kind of, I do not know, measure, I mean, I guess when you talk about vitality index, sometimes that can mean different things to different people because you could just be adjusting a product a little bit. Are you seeing more of an impact in your growth or your margins on the new product flow? That sometimes can answer that question a bit.

Yeah, I would say it is both. On the growth side, in our vitality index, which last year was about 35%, we are targeting a similar number for this year. The current mix is about 60% replace, 40% growth. To your point, we need to continue to drive improvement to be able to see more around the 50/50 mix between grow and replace. In the quarter, as we mentioned on the call, we were able to move our R&D investment more into the growth space, ultimately then leading to more growth coming out of the innovation engine. We are seeing nice progress. We have a lot of work going on in the front end space to be able to continue to see that improvement to get to a targeted 50/50. We have used a lot of AI tools.

We have AI agents running in two of our businesses to be able to speed up the front end. What used to take us about three months to move something from stage zero into stage one is now taking about five days because of the improvement that we have driven on using AI to be able to speed up that front end. It is both a growth and a margin improvement story. On the last year's basis, we saw about 150 basis points of margin lift from the investment that we are making in replace. The replace is not only to keep our product relevant and differentiated in the market, it also helps us on the productivity side to be able to input lower raw material costs and be able to get those requalified. That is primarily what we see on the replace side.

Okay. That's super helpful. Have you had to change the entire organization around how you really deliver that kind of product flow, getting closer to the customer or closer to the facilities? I mean, DuPont, I think historically, always centralized a lot of its R&D. Have you guys kind of culturally and physically changed that?

Yeah. There's really no centralized R&D anymore. It all sits within the businesses and under the businesses' P&L and responsibility. That was one big change that we made several years ago that we continue to keep in place because they obviously know what the customer wants, which feeds our innovation engine. That's been a nice piece of it. Another piece is really just around the discipline that we've introduced into the system. We've got all the data in one place where we can see where we're making our investments and making sure that we're differentially investing. We spend about 2.5% of sales in total on R&D, and that's differentially applied to the different businesses to make sure that we're investing more heavily in those that have higher growth entitlement.

We've been able to look, see where we're investing our resources, making sure that we're investing them back to the 80/20 work that applies to R&D investment as well, making sure that the R&D is being invested into the 80 and making sure that we grow the 80, so that we can see overall lift improvement with respect to growth.

Okay. Super helpful. Thanks, Lori, and best of luck to you guys for the rest of the year.

Our next question comes from the line of Joe Ritchie with Goldman Sachs. Your line is open.

I just wanted to first touch on the revenue beat this quarter. I think it was a little over $30 million higher than what the guide was for the quarter. I am just wondering, how much of that came from additional price that you put through versus just the volume recovery that you are seeing across some of the end markets that you highlighted earlier?

Hey, Joe, it's Antonella. Of the $30 million beat or so, about $10 million came from incremental price that got put into place in the quarter, and the other $20 million was more from volume.

Okay, got it. That's helpful, Antonella. Just a quick question. Obviously nice to see how aggressive you guys are being from a share buyback perspective. As we kind of think out beyond the fourth quarter, should we start penciling in a $250 million buyback? Just how are you guys thinking about that versus your other M&A priorities? Because I know you still want to change the mix of your business to be more Healthcare & Water Technologies-focused.

Yeah. Joe, I would say, we do have a lot of financial flexibility given where we are. We have a nice position of cash on the balance sheet, and our net debt to EBITDA is at 1.1x, so we have a lot of balance sheet flexibility as well. I view the buybacks as us being more opportunistic versus saying that we have an automatic $250 a quarter. Again, we have the flexibility. Given any timing of potential M&A will determine how much we are doing relative to share buybacks.

Our next question comes from the line of John McNulty with BMO Capital Markets. Your line is open.

Yeah, good morning. Thanks for taking my question. Had actually two for the DI side. Maybe the first one just on the construction piece. You seem to be doing a lot better than some of the other players in that end market. I guess, can you speak to the drivers behind that? It sounds like some of it's around kind of maybe a better approach from a building envelope side. Just curious if that's the heavier weighting or if it's more about the specific end markets that you're maybe having access to, whether it's data centers or fabs or what have you. I guess maybe just unpack some of the growth that you're seeing in that business for us. That'd be great.

Sure. There's a couple things let me talk about here. When you kind of take a look at our Building Technologies business, I would first say, the team has done a really good job in what has been a relatively tough market, I would say, over the last five years at this point. We are definitely outperforming the overall market based upon the weightings of where we play would suggest that the overall market is down low single digits, and our business has performed really well. I would bifurcate that between volume and price. From a volume perspective, I would say, we're expect to be relatively flat, and that's compared to a down market, and then we are getting pricing as well, which is really helping to drive the organic growth up.

But where that's coming from, the outperformance relative to the market, is really in two factors. We have some share gains, and we also have some favorable mix as well. Just to unpack that a little bit more for you, when you think about the national builders and the large regional builders, we do see more conversions to our house wrap, to Tyvek. That's clearly benefiting for us. And then also, we've talked before that we do have a nice presence in the multifamily. Within multifamily, increased penetration in that area typically brings, I would say, a broader bundle sale as well. That's helping to drive the revenue as well.

Got it. No, that's really helpful color on it. I guess the second piece would be more on the industrial side. The last couple of quarters, you've kind of highlighted aerospace as kind of a big crown jewel. I guess, can you help us to scale that business and maybe think about the backlog that you see and how that may be playing out as we look out, say, into 2027?

Yeah. Aerospace has done quite well for us. It's about $300 million or 3% of revenue or so, but really growing in the double-digit range, and the backlog that we have is quite sizable as well. This is one of our businesses across the whole portfolio where we do have more visibility than others. We generally can start each quarter with a full order book and start each year with a pretty good sign of where we'll land. We had highlighted on the call a nice win we had with our Vespel business. We've got really great relationships with all the large OEMs. On the Tedlar side, the same thing.

Vespel is more within the engine, Tedlar's more within the body of the plane, and both of them are seeing the similar amount of kind of low double-digit growth, and we continue to see that level of growth for the foreseeable future.

Great. Thanks very much for the color. Congratulations.

Our next question comes from the line of Chigusa Katoku with JPMorgan. Your line is open.

Hi, good morning. Thanks for taking my question. My first question—

—on the Diversified Industrials margins, I think they were especially stronger than what I had expected. Understanding you're driving a lot of good productivity, just curious to know what drove the outperformance. Then I think it's just expected to step down sequentially in the fourth quarter, so what's driving that too?

Yeah. We've seen really nice margin improvement within DI every quarter this year. Part of it is a little bit of favorable mix, obviously, to the conversation we just had with the low double-digit growth within aerospace. That does have a really nice margin portfolio for us to be able to drive improvement. The other piece is just the focus on productivity in the 80/20 that we're feeling within that business. We've called out a few times the opportunities that we have from an 80/20 perspective that we've been piloting within test businesses within DI. We continue to believe that we'll see a few million dollars of benefit this year from the 80/20 work, and then kind of a runway to tens of millions on the initial scope that we first put in place, which was about $700 million of revenue.

We've since expanded that 80/20 work to the MOLYKOTE business, which is about a $200 million business, and we see a few million dollars of opportunity there on the pricing side, where we put the 80/20 methodology to work. Just really nice improvement, really nice focus on productivity. We've had some businesses that have had assets that have run sold out, and we've driven sizable improvement within capacity release that have helped the margin profile as well.

Okay. Then, as a follow-up on the pricing side, I think you just earlier mentioned about $10 million of incremental price this quarter. I guess, a few bits with pricing closer to maybe 3% this quarter. Are you offsetting inflation on a dollar-for-dollar basis, or maybe better? Then how should we think about it, heading into next quarter?

Yep. We are offsetting inflation on a dollar basis. I would say for the full year versus the $90 million of pricing we had previously discussed, that is now closer to $110 million. You could expect that the fourth quarter pricing will be pretty similar to the third quarter pricing that you are seeing as well. Again, obviously, the team continues and will continue to, as prices continue to move, to take action to make sure that we continue to offset any incremental costs.

Our next question comes from the line of Chris Parkinson with Wolfe Research. Your line is open.

Great. Thank you so much for asking my question. Just want to drill down a little bit more into Healthcare Tech. You have been consistently citing basically broad-based trends across the portfolio, but for intermediate to long term, do you see any kind of further divergence between the personal protection market versus more of the med packaging? It seems like there is some kind of some newer products in there that could actually affect the growth rate. Just trying to get to the heart of the longer term growth algo within that business by sub-segment. Thank you.

Yeah. There is a bit of a bifurcation underneath the Tyvek business in general, which is what you're referring to. We've got, in broadly in healthcare, there's Tyvek, which is about $1 billion, and the remaining $800 million or $900 million or so is the med device businesses, with Liveo and Spectrum. On the Tyvek side, the med packaging is about half of the revenue, and the garments is about the other half. Garments will generally grow alongside industrial production, give or take, in the 2%-3% range. And med packaging will more be along the surgical procedures, which are in the mid-single digit range. We've got nice opportunity to continue to drive expansion in both.

We talked about Tyvek with the renewable attribution on the call, that will give us a more profile that is in line with the sustainability initiatives of our customers. On the garment side, we've talked in previous calls about the APX garments, which are coming out that provide more comfort and flexibility and breathability that'll allow us to be competitive within the garment space. Overall, the net Tyvek should be butting up against 4% from a volume perspective, and then we obviously expect to drive above market growth just based on the investments that we're making in the business. They'll generally be about 2%-3% alongside industrial production for garments, and then in the 5-ish percent range for the med packaging side.

That's very helpful. Just as a follow-up, Lori, we're exactly one year, more or less, following the Qnity spin. I think everybody always focuses on the company that's been spun out and the opportunities for independence. I'd love to give you the opportunity to say, what have you been doing differently? What are you satisfied with year one in terms of the more nimble industrial portfolio, and what should we be looking forward to for 2027, 2028? Thank you.

Yeah. It has been a year, November 1st, and both of us are off to a really great start. Qnity continues to produce really, really strong top-line growth. They're squarely in the AI data center trade, and they have a lot of runway on the multiple side. They should be up with Entegris, in my opinion. They've got a lot of room for opportunity to drive growth. On the DuPont side, I'm super proud of what we've driven out of the gate as well. We are at the top end or above our medium-term targets that we just put out a year ago, on all metrics, on growth, on margin expansion, on EPS, and on free cash flow generation. Off to a really great start.

What makes me the most proud is it's a nice mix of both the top and the bottom line. It's driving growth, it's really focusing in on our innovation excellence and in our growth rooms and our commercial excellence opportunities that you're seeing play out, especially in a pretty choppy market. When you consider that we've got 4.5% organic growth this year, we still have about 40% of our portfolio that's down on the construction side and the automotive side. When you look at those two markets, low single-digit declines in both, and we're still posting 4.5% growth, kind of speaks to the quality of our portfolio on the growth side. Then on the productivity perspective, I would say we're a little ahead of where I would have expected to be.

So we said 50-70 basis points or so a year of annual lift, and we're sitting at 80 with a headwind of about 40 from price-cost. So really nice, strong performance out of the gate. So I'm just really proud of the team. I see a lot of momentum going forward. We've got a very energized, quite young team, to be honest, so I'm really happy with where we're sitting.

Our next question comes from the line of John Roberts with Mizuho. Your line is open.

Thank you. Nice quarter and nice guidance. How does the bolt-on pipeline look in both the water and healthcare areas? Is the increased buyback a sign that it is kind of thin right now, and are higher interest rates affecting deal activity?

No, I mean, the pipeline remains robust, so we have got enough cash to be able to do both. Since we came out of the gate, we have announced the intent to buy back about 7% of our shares, so a nice improvement there, and it still leaves us with about $1.5 billion of firepower to be able to do some accretive growth M&A. So, we have just been really diligent about what we are going after. We have got a defined set of financial parameters that we are operating within, and we have assets that can check those boxes. We are just being prudent and playing the process along the way. I still am looking for some M&A opportunities, but we are not going to make a hasty decision and do a deal just to do a deal.

We are going to make one that is right down the middle of the fairway, and you can see really good returns on our end. In the meantime, trading below 12 for the high-quality portfolio that we have tells me I should be buying back my shares whenever I can.

Okay. Back to Building Technologies. Have raw materials stabilized in that segment now?

Yeah, I mean, overall, obviously, we continue to look at both where the price of oil is as well as the price of natural gas, as we have some production in Europe as well. As you saw in our results this quarter, as things move, we will act, and we will move as well, and we have clearly offset all of our inflationary costs.

Our next question comes from the line of Josh Spector with UBS. Your line is open.

Yeah. Hi, good morning. I wanted to follow up on some of the productivity comments. I think you said 2% net productivity achieved in the quarter that delivered something like 90 basis points margin improvement, maybe more. What does the 3% net productivity mean as it relates to your algo? Does that mean you should be delivering greater than 50-70 basis points of margin improvement as you look over the next couple years, or are you reinvesting that someplace within the business that we should see that offset?

Yeah, I think you guys got to make sure you don't double count, because we're talking about net productivity within COGS. We will take those costs out. Some of those costs help to offset inflationary pressures in other areas of the P&L, because that 3% is net in COGS, so it'll take care of inflation in that space. But you obviously have some inflation in SG&A, and then to your point, there are some investments as well. For example, if you look at our third quarter performance and our overall 90 basis points of margin expansion we had, about 120 basis points of that was driven by the combination of growth and productivity benefits, offset by oil and gas inflation, and then we had a little other positives from some FX moves in there that got us to the 90 basis points overall.

Just to keep in mind, as Lori Koch mentioned earlier, that net productivity target does include the benefit of volume, so you just got to put that into the equation as well.

Yeah, and the oil and gas inflation was just a margin headwind, so we were full on a cost dollar basis. It's just that the math suggests a margin headwind.

Okay. No, I appreciate that. That's very helpful. I did want to follow up quickly just on water organic. Looking at your reporting this year, the Middle East each quarter has been like a low single-digit headwind. If things stay as they are, is the base business going enough that we could see mid-single-digit growth return next year, assuming the Middle East stays as it is, understanding that's a pretty big assumption?

Yeah, I mean, if you look at our full-year expectations for water right now, there is about 1% organic growth baked into our guide with the push that we made on the Middle East projects. If you take out the Middle East from those numbers, we would be up more in the mid-single-digit range alongside where the GWI, the Global Water Index, sit. Assuming no material improvement or deceleration in the Middle East for next year, then you would expect us to again be in line with where the Global Water Index is, which has generally been in the 4%-4.5% range.

We have got really nice performance outside the Middle East that has been able to give us overall low single-digit growth, but obviously, we have been impacted by that. But we have not lost the I mean, it is one business, and so it is just a matter of when the stabilization happens in the region so that we can ship the materials, but the business is not.

Our next question comes from the line of David Begleiter with Deutsche Bank. Your line is open.

Hey, good morning. Lori, a little bit more on that question. Looking into 2027, early look, what is in your control, what is not in your control, and what could that mean for EBITDA growth? I see consensus up 5% year-over-year. I think you can probably do better than that, but any early thoughts on 2027? Thank you.

Yeah, we will give full color on 2027 on the next call, but as of right now, if we look at it kind of strictly from an end market perspective, let's leave the Middle East conversation that we just had to the side, we kind of see a similar end market performance with a slight improvement in automotive. This year, automotive is down 1.5%-2%. I think the initial expectation for next year is to be up slightly. Every other end market, we are generally thinking would be consistent. Nice mid-single-digit growth in healthcare markets, nice mid-single-digit growth in water ex the Middle East situation, kind of a similar environment within the construction space, and generally similar environment in the 3%-4% range for industrial production.

Given that top line algorithm, we should and the productivity initiatives that we still have in place, then you would continue to expect to us be able to compound some margin expansion on top of a top line opportunity that's pretty similar to this year. BWe will give full color as we get into 2027.

Very helpful. Just on pricing, how much pricing is being carried over to next year? I know most of this is surcharges, but how much pricing tailwind could you get for benefit from 2027?

We started predominantly our pricing actions in May of this year, so it was kind of in the middle of the second quarter. So clearly, you will have a full carryover effect into Q1 and part of that into the second quarter as well.

DuPont (DD) Q3 2026 Earnings Call Transcript

Company Participants